In patients with end-stage renal disease, GLP-1 RA use was also associated with lower all-cause mortality (HR 0.64; 95 % CI: 0.54–0.76) and fewer hospitalizations (HR 0.64; 95 % CI: 0.57–0.71) (Table 3, Fig. 2B). This evidence concerns the gene GLP1R and stage 5 chronic kidney disease.